0.14
+0.01(+7.69%)
Currency In CAD
Address
3400 One First Canadian Place
Toronto, ON M5X 1A4
Canada
Phone
N/A
Website
Sector
Healthcare
Industry
Biotechnology
Employees
N/A
First IPO Date
March 30, 2010
| Name | Title | Pay | Year Born |
| Gadi Levin | Chief Executive Officer & Chairman | 53,000 | 1973 |
| Alan Mark Rootenberg | Chief Financial Officer | 13,000 | 1952 |
| Riva Kovjazin | Senior Scientist & Member of Scientific Advisory Board | 0 | N/A |
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.